Drugmaker Endo Pharmaceuticals announced Thursday that it received U.S. approval for its long-acting testosterone injection Aveed, which joins a crowded field of hormone-boosting drugs aimed at aging American men.
The Irish drugmaker said the Food and Drug Administration approved Aveed for men with low testosterone, a condition sometimes associated with fatigue, weight gain and low libido. Endo’s injection is to be taken once every 10 weeks, versus weekly or biweekly dosing for currently available products. The company said in a statement it expects to launch the drug this month. The Dublin-based company already markets Fortesta, a prescription gel form of testosterone, the male hormone that begins to decline after age 40.